Identification

Name
Celiprolol
Accession Number
DB04846
Type
Small Molecule
Groups
Approved, Investigational
Description

Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall). Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

Structure
Thumb
Synonyms
  • RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
External IDs
REV 5320 A / ST 1396 / UL/1677
International/Other Brands
Cardem / Celipres / Celipro / Celol / Cordiax / Dilanorm / Selectol (Sanofi)
Categories
UNII
DRB57K47QC
CAS number
56980-93-9
Weight
Average: 379.501
Monoisotopic: 379.247106555
Chemical Formula
C20H33N3O4
InChI Key
JOATXPAWOHTVSZ-UHFFFAOYSA-N
InChI
InChI=1S/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)
IUPAC Name
1-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-3,3-diethylurea
SMILES
CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O

Pharmacology

Indication

Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Celiprolol is a vasoactive beta-1 selective adrenoceptor antagonist with partial beta-2 agonist activity. The beta-2 agonist activity is thought to account for its mild vasodilating properties. It lowers blood pressure in hypertensive patients at rest and on exercise. The effects on heart rate and cardiac output are dependent on the pre-existing background level of sympathetic tone. Under conditions of stress such as exercise, celiprolol attenuates chronotropic and inotropic responses to sympathetic stimulation. However, at rest minimal impairment of cardiac function is seen.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
agonist
Human
Absorption

Absorption of an oral dose is rapid and consistent but incomplete (55% for 200 mg dose and 74% for 400 mg dose) from the gastrointestinal tract. The bioavailability of celiprolol has been shown to be markedly affected by food and one should avoid administration of celiprolol with food. Coadministration of chlorthalidone, hydrochlorothiazide and theophylline also reduces the bioavailability of celiprolol. Following oral dosing, maximal blood concentrations are reached between 2 and 3 hours.

Volume of distribution

The distribution volume is 4.5L/kg. Celiprolol is hydrophilic and does not cross the blood-brain barrier. The binding to plasma proteins is about 25-30%.

Protein binding

25-30%.

Metabolism

A 14C labelled dose was completely recovered within 48 hours. The first-pass effect in the liver is insignificant. Celiprolol is metabolized to a minor extent (1-3%).

Route of elimination
Not Available
Half life

5 hours

Clearance

Cleared by both renal and non-renal excretory pathways. Celiprolol is not recommended for patients with creatinine clearance less than 15 mL per minute.

Toxicity

No data are available regarding celiprolol overdose in humans. The most common symptoms to be expected following overdosage with beta-adrenoceptor blocking agents are bradycardia, hypotension, bronchospasm and acute cardiac insufficiency.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Celiprolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Celiprolol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Celiprolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Celiprolol.Approved
AcemetacinAcemetacin may decrease the antihypertensive activities of Celiprolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Celiprolol.Approved
AcetohexamideCeliprolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Acetylcholine.Approved
AcetyldigitoxinCeliprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinCeliprolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Celiprolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Experimental, Investigational
AlaproclateThe serum concentration of Celiprolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Celiprolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Celiprolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Celiprolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
AliskirenCeliprolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Celiprolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Celiprolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Celiprolol.Approved
AmbrisentanCeliprolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateCeliprolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineCeliprolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Celiprolol.Illicit, Withdrawn
AminophyllineCeliprolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Celiprolol.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Celiprolol.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Celiprolol.Approved
AmobarbitalThe serum concentration of Celiprolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Celiprolol can be decreased when combined with Amodiaquine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Celiprolol.Approved, Illicit
AndrographolideAndrographolide may decrease the antihypertensive activities of Celiprolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Celiprolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Celiprolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Celiprolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
AprepitantThe serum concentration of Celiprolol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineCeliprolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Arecoline.Experimental
ArformoterolCeliprolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AtazanavirThe metabolism of Celiprolol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may decrease the bronchodilatory activities of Celiprolol.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Celiprolol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Celiprolol is combined with Atosiban.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Celiprolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Celiprolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
BambuterolCeliprolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneThe serum concentration of Celiprolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Celiprolol can be decreased when it is combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Celiprolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Celiprolol.Experimental
BendroflumethiazideCeliprolol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Celiprolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Celiprolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Celiprolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Illicit
BepridilBepridil may increase the hypotensive activities of Celiprolol.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Celiprolol can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Celiprolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Celiprolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Celiprolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Celiprolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
BisoprololBisoprolol may decrease the bronchodilatory activities of Celiprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Celiprolol.Investigational
BoceprevirThe metabolism of Celiprolol can be decreased when combined with Boceprevir.Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Celiprolol.Approved
BortezomibThe metabolism of Celiprolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Celiprolol can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Celiprolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Celiprolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Celiprolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Celiprolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Celiprolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Celiprolol.Investigational
BucindololCeliprolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Celiprolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Celiprolol.Experimental
BumetanideCeliprolol may increase the hypokalemic activities of Bumetanide.Approved
BunazosinCeliprolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Celiprolol.Approved, Investigational
BupranololCeliprolol may increase the hypotensive activities of Bupranolol.Approved
CabergolineCeliprolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Celiprolol.Experimental
CafedrineCeliprolol may increase the hypotensive activities of Cafedrine.Investigational
CandesartanCandesartan may increase the hypotensive activities of Celiprolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Celiprolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Celiprolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Celiprolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Celiprolol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Celiprolol.Experimental
CarbutamideCeliprolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Celiprolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Celiprolol.Approved
CarvedilolCeliprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Celiprolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Celiprolol can be increased when it is combined with Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Celiprolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideCeliprolol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Celiprolol.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Celiprolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
ChlorpropamideCeliprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneCeliprolol may increase the hypokalemic activities of Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Celiprolol.Approved
CicletanineCeliprolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Celiprolol.Approved
ClarithromycinThe metabolism of Celiprolol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Celiprolol can be decreased when combined with Clemastine.Approved
ClenbuterolCeliprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Celiprolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Celiprolol.Approved
CloranololCeliprolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Celiprolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Celiprolol can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Celiprolol can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Celiprolol.Vet Approved
CrizotinibThe metabolism of Celiprolol can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Celiprolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Celiprolol.Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Celiprolol.Approved
CyclopenthiazideCeliprolol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Celiprolol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Celiprolol.Approved
CymarinCeliprolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Celiprolol.Investigational
DabrafenibThe serum concentration of Celiprolol can be decreased when it is combined with Dabrafenib.Approved
DapoxetineThe serum concentration of Celiprolol can be increased when it is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Celiprolol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Celiprolol can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Celiprolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Celiprolol.Approved
DeferasiroxThe serum concentration of Celiprolol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilCeliprolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Celiprolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Celiprolol.Approved
DeserpidineCeliprolol may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Celiprolol.Approved
DeslanosideCeliprolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Celiprolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Celiprolol.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Celiprolol.Experimental
DichlorvosDichlorvos may increase the bradycardic activities of Celiprolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
diethylnorspermineCeliprolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Celiprolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Celiprolol.Approved
DigitoxinCeliprolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinCeliprolol may increase the bradycardic activities of Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Celiprolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
DiltiazemThe metabolism of Celiprolol can be decreased when combined with Diltiazem.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Celiprolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Celiprolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Celiprolol.Experimental
DobutamineCeliprolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Celiprolol.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Celiprolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Celiprolol.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Celiprolol.Approved
DoxazosinCeliprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Celiprolol.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Doxofylline.Approved
DoxycyclineThe metabolism of Celiprolol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolDronabinol may increase the tachycardic activities of Celiprolol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Celiprolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Celiprolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
DuloxetineThe serum concentration of Celiprolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Celiprolol.Investigational
DyphyllineCeliprolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Celiprolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Celiprolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Celiprolol.Approved
EfonidipineCeliprolol may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
EnalaprilatCeliprolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Celiprolol.Experimental
EnzalutamideThe serum concentration of Celiprolol can be decreased when it is combined with Enzalutamide.Approved
EpanololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Nutraceutical, Withdrawn
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Celiprolol.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Celiprolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Celiprolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Celiprolol.Approved
Ergoloid mesylateCeliprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineCeliprolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
ErythromycinThe metabolism of Celiprolol can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Celiprolol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Celiprolol.Approved
Etacrynic acidCeliprolol may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Celiprolol.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Etilefrine.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Celiprolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
EtoperidoneThe serum concentration of Celiprolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Celiprolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Celiprolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Celiprolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Celiprolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Celiprolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Celiprolol.Approved
FenoterolCeliprolol may decrease the bronchodilatory activities of Fenoterol.Approved
FenozoloneThe risk or severity of adverse effects can be increased when Celiprolol is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Celiprolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Celiprolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Celiprolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Celiprolol.Experimental
Ferulic acidCeliprolol may increase the hypotensive activities of Ferulic acid.Experimental
FingolimodCeliprolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Celiprolol.Approved, Withdrawn
FluconazoleThe metabolism of Celiprolol can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Celiprolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Celiprolol.Experimental
FluoxetineThe serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Celiprolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
FluvoxamineThe metabolism of Celiprolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolCeliprolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Celiprolol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Celiprolol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Celiprolol.Approved
FosphenytoinThe metabolism of Celiprolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
FurosemideCeliprolol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Celiprolol can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Celiprolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Celiprolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Celiprolol.Approved, Nutraceutical
GitoformateCeliprolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideCeliprolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideCeliprolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideCeliprolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneCeliprolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideCeliprolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideCeliprolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Celiprolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Celiprolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Celiprolol.Approved
GuanazodineCeliprolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Celiprolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
GuanoclorCeliprolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCeliprolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCeliprolol may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Celiprolol.Experimental
HexamethoniumCeliprolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Celiprolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Celiprolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Celiprolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Celiprolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Celiprolol.Approved
HydrochlorothiazideCeliprolol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCeliprolol may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe metabolism of Celiprolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Celiprolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Celiprolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Celiprolol.Approved
IdelalisibThe serum concentration of Celiprolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
ImatinibThe metabolism of Celiprolol can be decreased when combined with Imatinib.Approved
ImidaprilCeliprolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Celiprolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Celiprolol.Approved
IndacaterolCeliprolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Celiprolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideCeliprolol may increase the hypokalemic activities of Indapamide.Approved
IndenololCeliprolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Celiprolol can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Celiprolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Celiprolol.Withdrawn
IndoraminCeliprolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkCeliprolol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Celiprolol.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Celiprolol.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Celiprolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Celiprolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Celiprolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
IsavuconazoniumThe metabolism of Celiprolol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Celiprolol.Approved
IsoetarineCeliprolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Celiprolol.Approved, Withdrawn
IsoprenalineCeliprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Celiprolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Celiprolol can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Celiprolol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Celiprolol can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Celiprolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Celiprolol.Investigational
KetoconazoleThe metabolism of Celiprolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Celiprolol.Approved
LabetalolCeliprolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineCeliprolol may increase the hypotensive activities of Lacidipine.Approved
Lanatoside CCeliprolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
LevomilnacipranThe serum concentration of Celiprolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
LevosalbutamolCeliprolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Celiprolol.Approved, Vet Approved
LinezolidLinezolid may increase the hypertensive activities of Celiprolol.Approved, Investigational
LinsidomineCeliprolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Celiprolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Lobeline.Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Celiprolol.Experimental
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Celiprolol.Experimental
LopinavirThe metabolism of Celiprolol can be decreased when combined with Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Celiprolol.Approved
LosartanLosartan may increase the hypotensive activities of Celiprolol.Approved
LovastatinThe metabolism of Celiprolol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Celiprolol.Approved
LuliconazoleThe serum concentration of Celiprolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Celiprolol can be increased when combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
MacitentanCeliprolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Celiprolol.Approved
MalathionMalathion may increase the bradycardic activities of Celiprolol.Approved, Investigational
ManidipineCeliprolol may increase the hypotensive activities of Manidipine.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Celiprolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Celiprolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Celiprolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Celiprolol.Approved
MefenorexThe risk or severity of adverse effects can be increased when Celiprolol is combined with Mefenorex.Experimental
MefloquineMefloquine may increase the bradycardic activities of Celiprolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Celiprolol.Approved, Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Celiprolol.Approved
MepindololMepindolol may decrease the bronchodilatory activities of Celiprolol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Celiprolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Celiprolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Celiprolol.Approved
MetahexamideCeliprolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Celiprolol.Withdrawn
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Celiprolol.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Celiprolol.Investigational
MethohexitalThe serum concentration of Celiprolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineCeliprolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Celiprolol.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Celiprolol.Approved
MethyclothiazideCeliprolol may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Celiprolol.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Celiprolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Celiprolol.Investigational
MethylergometrineCeliprolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Celiprolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinCeliprolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Celiprolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Celiprolol.Approved, Investigational
MetolazoneCeliprolol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
MetyrosineCeliprolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Celiprolol.Withdrawn
MidodrineCeliprolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Celiprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Celiprolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Celiprolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Celiprolol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Celiprolol.Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Celiprolol.Approved
MitotaneThe serum concentration of Celiprolol can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Celiprolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Celiprolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Celiprolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Celiprolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Celiprolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Celiprolol.Approved, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
MuzolimineCeliprolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Celiprolol.Approved
NabiloneNabilone may increase the tachycardic activities of Celiprolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Celiprolol.Approved
NadololNadolol may increase the hypotensive activities of Celiprolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Celiprolol.Approved
NaftopidilCeliprolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
NebivololNebivolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
NefazodoneThe metabolism of Celiprolol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Celiprolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Celiprolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Celiprolol.Approved
NetupitantThe serum concentration of Celiprolol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Celiprolol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Celiprolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Celiprolol.Approved
NicorandilCeliprolol may increase the hypotensive activities of Nicorandil.Approved
NicotineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Celiprolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Celiprolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Celiprolol.Approved
NiguldipineCeliprolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Celiprolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineCeliprolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Celiprolol.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Celiprolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Celiprolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Celiprolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Celiprolol.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Celiprolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Celiprolol.Approved
NylidrinThe risk or severity of adverse effects can be increased when Celiprolol is combined with Nylidrin.Approved
ObinutuzumabCeliprolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Celiprolol.Withdrawn
OlaparibThe metabolism of Celiprolol can be decreased when combined with Olaparib.Approved
OleandrinCeliprolol may increase the bradycardic activities of Oleandrin.Experimental
OlmesartanOlmesartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
OlodaterolCeliprolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Celiprolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Celiprolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Celiprolol.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Celiprolol.Investigational
OrciprenalineCeliprolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Celiprolol.Vet Approved
OsimertinibThe serum concentration of Celiprolol can be increased when it is combined with Osimertinib.Approved
OuabainCeliprolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Celiprolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Celiprolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Celiprolol.Withdrawn
PalbociclibThe serum concentration of Celiprolol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Celiprolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Celiprolol.Approved
PargylinePargyline may increase the hypotensive activities of Celiprolol.Approved
ParoxetineThe serum concentration of Celiprolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Celiprolol.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
PentobarbitalThe metabolism of Celiprolol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Celiprolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Celiprolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Celiprolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Celiprolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Celiprolol.Approved
PeruvosideCeliprolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Celiprolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Celiprolol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Celiprolol.Approved, Illicit
PhenobarbitalThe metabolism of Celiprolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Celiprolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Celiprolol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Celiprolol.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Celiprolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Celiprolol.Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Celiprolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Celiprolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Celiprolol.Withdrawn
PindololPindolol may increase the hypotensive activities of Celiprolol.Approved
PirbuterolCeliprolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PiretanideCeliprolol may increase the hypokalemic activities of Piretanide.Experimental
PirfenidonePirfenidone may decrease the antihypertensive activities of Celiprolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Celiprolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Celiprolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Celiprolol.Withdrawn
PolythiazideCeliprolol may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Celiprolol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Celiprolol.Experimental
PrazosinCeliprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Celiprolol is combined with Prenalterol.Experimental
PrimaquineThe metabolism of Celiprolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Celiprolol can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolCeliprolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Celiprolol.Experimental
PromazinePromazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Celiprolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Celiprolol.Approved
PropafenoneThe serum concentration of Celiprolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Celiprolol.Vet Approved
PropranololPropranolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Celiprolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Celiprolol.Experimental
ProscillaridinCeliprolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Celiprolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Celiprolol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
QuinethazoneCeliprolol may increase the hypokalemic activities of Quinethazone.Approved
QuinineQuinine may increase the hypotensive activities of Celiprolol.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Racepinephrine.Approved
RamiprilRamipril may increase the hypotensive activities of Celiprolol.Approved
RanolazineThe metabolism of Celiprolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Celiprolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Celiprolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Celiprolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Celiprolol.Approved
RescinnamineCeliprolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Celiprolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Celiprolol.Experimental, Investigational
RifabutinThe metabolism of Celiprolol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Celiprolol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Celiprolol can be increased when combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Celiprolol.Investigational
RiociguatCeliprolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
RitodrineCeliprolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Celiprolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCeliprolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Celiprolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Celiprolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Celiprolol.Withdrawn
SalbutamolCeliprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Celiprolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
SalmeterolCeliprolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Celiprolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Celiprolol.Experimental
SaquinavirThe metabolism of Celiprolol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe serum concentration of Celiprolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Celiprolol.Approved, Investigational, Vet Approved
SelexipagCeliprolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Celiprolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Celiprolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Celiprolol.Investigational
SertralineThe serum concentration of Celiprolol can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
SilodosinCeliprolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Celiprolol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Celiprolol can be increased when it is combined with Simeprevir.Approved
SitaxentanCeliprolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Celiprolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Celiprolol.Investigational
St. John's WortThe serum concentration of Celiprolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Celiprolol can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the bradycardic activities of Celiprolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Celiprolol.Approved
SulfisoxazoleThe metabolism of Celiprolol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Celiprolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Celiprolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Celiprolol.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Synephrine.Experimental
TacrineTacrine may increase the bradycardic activities of Celiprolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
TalinololCeliprolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinCeliprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Celiprolol.Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Celiprolol.Approved
TelaprevirThe metabolism of Celiprolol can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Celiprolol can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
TemocaprilCeliprolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Celiprolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Celiprolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Celiprolol.Vet Approved
TerazosinCeliprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineCeliprolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Celiprolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Celiprolol.Approved, Investigational
TertatololTertatolol may decrease the bronchodilatory activities of Celiprolol.Experimental
TetrahydropalmatineCeliprolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tetryzoline.Approved
TheodrenalineCeliprolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineCeliprolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Celiprolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Celiprolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Celiprolol.Withdrawn
ThiopentalThe serum concentration of Celiprolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Celiprolol.Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Celiprolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Celiprolol.Approved
TiboloneCeliprolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Celiprolol can be decreased when combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Celiprolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Celiprolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Celiprolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
TocilizumabThe serum concentration of Celiprolol can be decreased when it is combined with Tocilizumab.Approved
TolazamideCeliprolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Celiprolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Celiprolol.Approved
TolonidineCeliprolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Celiprolol.Approved
TorasemideCeliprolol may increase the hypokalemic activities of Torasemide.Approved
TramazolineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tramazoline.Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Celiprolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Celiprolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Celiprolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Celiprolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Celiprolol.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tretoquinol.Experimental
TribenosideTribenoside may decrease the antihypertensive activities of Celiprolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Celiprolol.Vet Approved
TrichlormethiazideCeliprolol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Celiprolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Celiprolol.Approved, Vet Approved
TrimazosinCeliprolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Celiprolol.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Celiprolol.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Celiprolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Celiprolol.Approved
TyramineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Tyramine.Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Celiprolol.Approved, Investigational
UnoprostoneCeliprolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilCeliprolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Celiprolol.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Celiprolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Celiprolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Celiprolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Celiprolol can be decreased when combined with Verapamil.Approved
VilanterolCeliprolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineCeliprolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineCeliprolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Celiprolol can be decreased when combined with Voriconazole.Approved, Investigational
XipamideCeliprolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Celiprolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Celiprolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Celiprolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Celiprolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Celiprolol can be decreased when combined with Ziprasidone.Approved
ZofenoprilCeliprolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Celiprolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Zolss, G., Pittner, H., Stormann-Menninger-Lerchenthal, H. and Lindner, I.; US. Patent 3,983,169; September 28,1976; assigned to Chemie Linz AG (Austria).

General References
  1. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P: Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. [PubMed:20825986]
External Links
KEGG Drug
D07660
PubChem Compound
2663
PubChem Substance
310264853
ChemSpider
2563
ChEBI
94461
ChEMBL
CHEMBL27810
Drugs.com
Drugs.com Drug Page
Wikipedia
Celiprolol
ATC Codes
C07AB08 — Celiprolol
MSDS
Download (80.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCHROMOSOME 2q31.2 DELETION SYNDROME / EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120-122Zolss, G., Pittner, H., Stormann-Menninger-Lerchenthal, H. and Lindner, I.; US. Patent 3,983,169; September 28,1976; assigned to Chemie Linz AG (Austria).
Predicted Properties
PropertyValueSource
Water Solubility0.174 mg/mLALOGPS
logP2.29ALOGPS
logP1.5ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.55ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area90.9 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity108.25 m3·mol-1ChemAxon
Polarizability43.18 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0039000000-39adbc5dfd1bc8f5b669
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kb-0290000000-9ce22ac0f02d4aa4ece7
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0930000000-fda70a2855a32eef9dfb
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0910000000-2cd78270a6dd85856f66
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-a8bdc80a8e1a59ed7fbc
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0059-0900000000-854fe31d61307c2c7c53
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0009000000-1a45fe930a38f058bbf1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pir-2079000000-801b19d8f25b8e4380fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fk9-9270000000-9c357e3f78ea2c4ad1b7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9220000000-fc78f8368ad1492b4a0a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9300000000-444019d8fc1a8c096ab8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9300000000-87d751e98a384f2697c1

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
N-phenylureas / Acetophenones / Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Ureas / Secondary alcohols / 1,2-aminoalcohols
show 4 more
Substituents
Alkyl-phenylketone / N-phenylurea / Acetophenone / Phenoxy compound / Benzoyl / Aryl alkyl ketone / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Benzenoid
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Minatoguchi S, Arai M, Wang N, Lu C, Narentuoya B, Uno Y, Misao Y, Takemura G, Fujiwara T, Fujiwara H: Celiprolol, a selective beta1-blocker, reduces the infarct size through production of nitric oxide in a rabbit model of myocardial infarction. Circ J. 2007 Apr;71(4):574-9. [PubMed:17384462]
  2. Hayashi T, Juliet PA, Miyazaki-Akita A, Funami J, Matsui-Hirai H, Fukatsu A, Iguchi A: beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes. Life Sci. 2007 Jan 16;80(6):592-9. Epub 2006 Dec 1. [PubMed:17141277]
  3. Yao EH, Fukuda N, Matsumoto T, Katakawa M, Yamamoto C, Han Y, Ueno T, Kobayashi N, Matsumoto K: Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats. Am J Hypertens. 2008 Sep;21(9):1062-8. doi: 10.1038/ajh.2008.233. Epub 2008 Jul 17. [PubMed:18636069]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Hayashi T, Juliet PA, Miyazaki-Akita A, Funami J, Matsui-Hirai H, Fukatsu A, Iguchi A: beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes. Life Sci. 2007 Jan 16;80(6):592-9. Epub 2006 Dec 1. [PubMed:17141277]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G: Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm. 2008 May 22;356(1-2):351-3. doi: 10.1016/j.ijpharm.2007.12.028. Epub 2007 Dec 28. [PubMed:18242899]

Drug created on October 18, 2007 09:59 / Updated on October 02, 2017 05:39